drugset / Trial / NCT00318890
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
Phase 1/2
Completed
48 enrolled
University of Alabama at Birmingham
Aventis Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial seeks to accomplish both local and regional control of head and neck cancer and reduce systemic metastatic disease. To do this, patients will received chemotherapy followed by chemotherapy and radiation (given together) with an escalating dose of docetaxel.
Timeline
- Start
- 2002-10
- Primary completion
- 2007-04
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | amifostine | Unknown | — | Subcutaneous |